https://doi.org/10.17037/DATA.00003168
Antimicrobial resistance is a major global health concern, but there is limited data linking laboratory resistance testing to clinical outcomes, especially from Low-and-Middle-Income countries, including African nations. This is a project collecting prospective data about bloodstream infections caused by Enterobacterales bacteria in African hospitals in 2020-22. A central focus was the impact of 3rd generation cephalosporin (3GC) resistance on patient mortality. In the main study, n=8 hospitals in eight different countries contributed to this project. Preliminary work involved collection of descriptive information from these 8 hospitals, including access to antibiotics in hospital pharmacies. Information was collected for infected patients and matched non-infected patients in same hospitals.
The MBIRA study collected data about hospitals, patients, bacterial isolates and antibiotic use. The “mbira_hospital” dataset contains information collected as a one-off event as part of the “hospital” form and the “mbira_pharmacy” contains information on antibiotic availability in pharmacies that were collected each month. Further datasets will be made available at a later date.
The hospital-level data – this is in the form of two small data tables. One relates to the “hospital form” (a one-off data collection, see Appendix 1) and the second relates to the “antibiotic form” (repeated monthly collection of data about antibiotic availability in pharmacies, see Appendix 2). These are two small data tables (mbira_hospital.xls and mbira_pharmacy.xls) that are in the form of excel spreadsheets.
Variable name | Variable label | Answer label | Answer code | Variable type |
1 | Site ID | Numeric | ||
2 | Event Name | String | ||
Hospital profile survey (Arm 1: English) | ||||
3 | Repeat Instrument | Hospital profile | String | |
4 | Repeat Instance | Numeric | ||
5 | Data Access Group | String | ||
6 | 1. Date of hospital survey started | DD/MM/YYYY | Date | |
7 | 2. Full physical address | String | ||
8 | 3. Urban or rural ? | String | ||
Mixed urban and rural | ||||
Urban | ||||
Rural | ||||
9 | 4. Hospital type ? | String | ||
10 | 4a.if Other Hospital type please specify describe here. | String | ||
11 | 5. Hospital level | String | ||
12 | 6. Hospital total beds + cots total | Numeric | ||
13 | Total ICU beds | Numeric | ||
14 | ICU beds [total_icu_beds_sa] Level of ICU care | String | ||
15 | Total Paediatric ICU beds/cots | String | ||
16 | Paediatric ICU beds/cots [total_paediatric_bed_cot_sa] Level of ICU care | String | ||
17 | Total NICU cots | String | ||
18 | NICU cots [total_nicu_cots_sa] Level of ICU care | String | ||
19 | 8. Total hospital admissions in 2019 (round 1) or 2020 (round 2) [total_hospital_admissions] from 1st Jan to 31st Dec for relevant year | Numeric | ||
20 | 8a. Total hospital inpatient-days in 2019 (round 1) or 2020 (round 2) [total_hospital_inpatient_days] from 1st Jan to 31st Dec for relevant year | Numeric | ||
21 | Core component 1 total score: IPC programme ( [ipc_programme] / 100 ) | Numeric | ||
22 | Core component 2 total score: IPC guidelines ( [ipc_guidelines] / 100 ) | Numeric | ||
23 | Core component 3 total score: IPC education and training ( [ipc_education_training] / 100) | Numeric | ||
24 | Core component 4 total score: Health-care Associated Infection surveillance ( [associated_infection_surveillanc] / 100 ) | Numeric | ||
25 | Core component 5 total score: Multimodal strategies for implementation of IPC interventions ( [ipc_interventions] / 100 ) | Numeric | ||
26 | Core component 6 total score: Monitoring / audit of IPC practices and feedback ( [ipc_practices_and_feedback] / 100 ) | Numeric | ||
27 | Core component 7 total score: Workload, staffing and bed occupancy ( [staffing_and_bed_occupancy] / 100 ) | Numeric | ||
28 | Core component 8 total score: built environment, materials and equipment for IPC at the facility level ( [ipc_at_the_facility_level] / 100 ) | Numeric | ||
29 | Total score (= sum of all core Components above) | Numeric | ||
30 | Note: The completed full version of the IPC Self-assessment framework sheets will need to be scanned and loaded to the REDCap database | String | ||
31 | Section 1. Leadership Commitment (Q1-3) | String | ||
32 | Section 2. Accountability and Responsibilities (Q4-9b) | String | ||
33 | Section 3. AMS Actions (Q10-17b)PL | String | ||
34 | Section 4. Education and Training (Q18-20) | String | ||
35 | Section 5. Monitoring and Surveillance (Q21-24) | String | ||
36 | Section 6. Reporting and Feedback (Q25-28) | String | ||
37 | Total of all sections (sum of above scores) | String | ||
38 | Note: The completed full version of the Antimicrobial Stewardship assessment will need to be scanned and loaded to the REDCap database. | String | ||
39 | Date of hospital survey completed | DD/MM/YYYY | Date |
Variable name | Variable label | Answer label | Answer code | Variable type |
1 | Site ID | Numeric | ||
2 | Event Name | Hospital pharmacy Survey (Arm 1: English) | String | |
3 | Repeat Instance | Numeric | ||
4 | Data Access Group | String | ||
5 | 1. Date of pharmacy survey | DD/MM/YYYY | Date | |
6 | amoxicillin | String | ||
7 | co-amoxiclav | String | ||
8 | gentamicin | String | ||
9 | ciprofloxacin | String | ||
10 | ceftriaxone | String | ||
11 | cefotaxime | String | ||
12 | ceftazidime | String | ||
13 | amikacin | String | ||
14 | meropenem | String | ||
15 | imipenem | String | ||
16 | chloramphenicol | String | ||
17 | piperacillin-tazobactam | String | ||
18 | co-trimoxazole | String | ||
19 | Group 1 : Other cephalosporins | String | ||
No | ||||
Yes | ||||
20 | Group 2 : Other β-lactam, β-lactamase inhibitors (BLBI) | String | ||
No | ||||
Yes | ||||
21 | Group 3 : Other carbapenem antibiotics | String | ||
No | ||||
Yes | ||||
22 | Group 4 : Tigecycline | String | ||
No | ||||
Yes | ||||
23 | Group 5: Any other agents for resistant Gram-negative infections | String | ||
No | ||||
Yes | ||||
24 | Date survey form was completed | DD/MM/YYYY | Date | |
25 | Date data was entered | DD/MM/YYYY | Date |
Variable name | Variable label | Answer label | Answer code | Variable type |
Redcap data access group | Country of study hospital | String | ||
ethiopia | ||||
ghana | ||||
kenya | ||||
malawi | ||||
nigeriaabuja | ||||
south_africa | ||||
tanzania | ||||
zambia | ||||
Name of antibiotic | Name of antibiotic | String | ||
amikacin | ||||
amoxicillin | ||||
ceftriaxone | ||||
chloramphenicol | ||||
ciprofloxacin | ||||
co-amoxiclav | ||||
co-trimoxazole (septrin, eusaprim) | ||||
gentamicin | ||||
meropenem | ||||
piperacillin-tazobactam (tazocin) | ||||
Percent patients | Percentage of study patients that received treatment | Numeric | ||
drugavailable | Proportion of monthly study surveys where antibiotic described as being available | Numeric |